Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

CR Pharmaceutical Commercial and Innovent Biologics Forge Strategic Partnership to Build Integrated Health Management Ecosystem

Fineline Cube Jul 14, 2026
Company Deals

Dizal Pharmaceutical Secures $1.5 Billion Global Licensing Deal with AstraZeneca for Sunvozertinib in EGFR Exon20ins NSCLC

Fineline Cube Jul 14, 2026
Company Deals

GSK Terminates $2.2 Billion Neurodegenerative Disease Partnership with Alector Following Dual Clinical Failures

Fineline Cube Jul 14, 2026
Company Deals

Zhaoke Ophthalmology Acquires Global Rights to NVK002 for Myopia Control, Licenses U.S. Rights to Nevakar

Fineline Cube Jul 14, 2026
Company Deals

Sisram Medical Restructures DaxibotulinumtoxinA Partnership with Fosun Wanbang Through New Sublicense and Promotion Services Agreements

Fineline Cube Jul 13, 2026
Policy / Regulatory

China’s State Council Unveils “15th Five-Year” National Health Plan with Strong Support for Innovative Therapeutics and AI Integration

Fineline Cube Jul 14, 2026
Company Drug

Haisco Pharmaceutical Secures NMPA IND Acceptance for HSK60002 Tablets in Inflammatory Diseases

Fineline Cube Jul 14, 2026
Company Drug

B&K Corporation Completes Patient Enrollment in Phase II Diabetic Foot Ulcer Trial for Pro-101-2 rhPDGF-BB Therapy

Fineline Cube Jul 14, 2026
Drug

Ascletis Pharma Files IND Application for ASC10 with US FDA

Fineline Cube Jul 6, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) announced that it has filed an Investigational New Drug...

Company Drug

MabPharm’s CMAB017 Receives NMPA Approval for Clinical Study in Solid Tumors

Fineline Cube Jul 6, 2022

Taizhou-based monoclonal antibody (mAb) biosimilars specialist MabPharm Ltd (HKG: 2181) announced that it has received...

Company Deals

Zhejiang Medicine’s NovoCodex Subsidiary Receives RMB 402M Investment

Fineline Cube Jul 6, 2022

China-based Zhejiang Medicine Co., Ltd (SHA: 600216) announced that investors will inject a financial dose...

Company Deals

Medicilon Biomedical Plans RMB 2.16B Private Placement for R&D Expansion

Fineline Cube Jul 6, 2022

China-based Shanghai Medicilon Biomedical Co., Ltd has announced plans to raise RMB 2.16 billion (USD...

Company Drug

Hansoh Pharmaceutical’s Generic Ibrance Approved by NMPA

Fineline Cube Jul 6, 2022

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that it has received market approval...

Company Digital

Alibaba Health’s 2022 Financial Report Shows Revenue Growth, Net Loss

Fineline Cube Jul 6, 2022

China-based Alibaba Health Information Technology Ltd (HKG: 0241) released its 2022 financial report (for the...

Company Policy / Regulatory

Wuxi Biologics Set to Be Removed from US Restricted Trade List

Fineline Cube Jul 6, 2022

Wuxi Biologics (HKG: 2269) is reportedly on the verge of being removed from a US...

Policy / Regulatory R&D

CDE Releases 60th Batch of Chemical Generic Reference Preparations

Fineline Cube Jul 6, 2022

The Center for Drug Evaluation (CDE) has released the 60th batch of chemical generic reference...

Company Deals

Beijing Tianshi Tongda Raises RMB 140M for Autoimmune Disease Therapies

Fineline Cube Jul 5, 2022

China-based Beijing Tianshi Tongda Pharmaceuticals Technology Co., Ltd has reportedly raised RMB 140 million (USD...

Company Deals

Wuhan YZY Biopharma Raises RMB 200M for Bispecific Antibodies and COVID-19 Vaccine Development

Fineline Cube Jul 5, 2022

China-based Wuhan YZY Biopharma Co., Ltd has reportedly raised RMB 200 million (USD 29.8 million)...

Company Deals

Shandong Xinhua Pharmaceutical Inks Tech Transfer Deal for LXH-2201 with IMM

Fineline Cube Jul 5, 2022

China-based Shandong Xinhua Pharmaceutical Co., Ltd (HKG: 0719) has signed a technology transfer agreement with...

Drug

Shionogi Files NDA for S-217622 COVID-19 Antiviral Drug in China

Fineline Cube Jul 5, 2022

Japan-based Shionogi & Co., Ltd has submitted a New Drug Application (NDA) to the National...

Company Drug

InnoCare Pharma’s ICP-490 Receives NMPA Approval for Hematological Malignancies

Fineline Cube Jul 5, 2022

Beijing InnoCare Pharma (HKG: 9969) announced that it has received clinical trial approval from the...

Company Drug

Hrain Biotech and Novartis Receive Breakthrough Therapy Designations for CAR-T and Zolgensma

Fineline Cube Jul 5, 2022

The Center for Drug Evaluation (CDE) website indicates that Hrain Biotechnology Co., Ltd’s BCMA –...

Company Deals

Techbank Medical Closes RMB 100M Series A to Build Global Innovation Platform

Fineline Cube Jul 5, 2022

Shanghai Techbank Medical Technology Co., Ltd, a cardiovascular device maker, has reportedly closed its Series...

Company Deals

PackGene and Genemagic Partner on AAV Production and CDMO Services

Fineline Cube Jul 5, 2022

China-based PackGene LLC has entered into a partnership with compatriot firm Genemagic Biosciences Co., Ltd....

Company Drug

PersonGen BioTherapeutics’ TAA06 Receives Clinical Trial Approval for B7-H3 CAR-T Therapy

Fineline Cube Jul 5, 2022

The Center for Drug Evaluation (CDE) website indicates that PersonGen BioTherapeutics (Suzhou) Co., Ltd’s TAA06,...

Company Drug

Akeso Biopharma’s Cadonilimab Achieves National Delivery in China

Fineline Cube Jul 5, 2022

China-based biotech Akeso Biopharma (HKG: 9926) announced the national delivery of its cadonilimab (AK104), marking...

Company Drug

Sobi’s Anakinra (Kineret) Prioritized for Review in China for FMF Treatment

Fineline Cube Jul 5, 2022

The Center for Drug Evaluation (CDE) website indicates that Swedish Orphan Biovitrum AB’s (Sobi; BMV:...

Company Drug

Arctic Vision Enrolls First Patient in ARVN003 Phase III Trial for Presbyopia

Fineline Cube Jul 5, 2022

China-based ophthalmic therapies developer Arctic Vision announced the first patient enrollment in a Phase III...

Posts pagination

1 … 682 683 684 … 694

Recent updates

  • CR Pharmaceutical Commercial and Innovent Biologics Forge Strategic Partnership to Build Integrated Health Management Ecosystem
  • China’s State Council Unveils “15th Five-Year” National Health Plan with Strong Support for Innovative Therapeutics and AI Integration
  • Haisco Pharmaceutical Secures NMPA IND Acceptance for HSK60002 Tablets in Inflammatory Diseases
  • China’s NHSA Completes Preliminary Review of 2026 Medical Insurance Catalog with 91% Pass Rate for Basic Medicines
  • B&K Corporation Completes Patient Enrollment in Phase II Diabetic Foot Ulcer Trial for Pro-101-2 rhPDGF-BB Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

CR Pharmaceutical Commercial and Innovent Biologics Forge Strategic Partnership to Build Integrated Health Management Ecosystem

Policy / Regulatory

China’s State Council Unveils “15th Five-Year” National Health Plan with Strong Support for Innovative Therapeutics and AI Integration

Company Drug

Haisco Pharmaceutical Secures NMPA IND Acceptance for HSK60002 Tablets in Inflammatory Diseases

Policy / Regulatory

China’s NHSA Completes Preliminary Review of 2026 Medical Insurance Catalog with 91% Pass Rate for Basic Medicines

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.